公开(公告)号：US10112996B2

公开(公告)日：2018-10-30

申请号：US15014145

申请日：2016-02-03

Applicant: UCB Biopharma SPRL

Inventor： Helene Margaret Finney ,  Terence Seward Baker ,  Alastair David Griffiths Lawson ,  Karen Margrete Miller ,  Marc Roger de Ryck ,  Christian Gilbert J. Wolff

IPC: A61K39/395 ,  C07K16/28 ,  C07K16/00 ,  A61K39/00

Abstract: A Nav1.7 binding entity that after binding functionally modifies the activity of the ion channel, in particular an anti-Nav1.7 antibody or binding fragment thereof, pharmaceutical compositions comprising said antibodies, use of the antibodies and compositions comprising the same, in treatment, for example in the treatment/modulation of pain and processes for generating and preparing said antibodies.

公开(公告)号：US09957320B2

公开(公告)日：2018-05-01

申请号：US15180916

申请日：2016-06-13

Applicant: UCB BIOPHARMA SPRL

Inventor： Neil Gozzard ,  Alastair David Griffiths Lawson ,  Daniel John Lightwood ,  Roger Thomas Palframan ,  Bryan John Smith ,  Kerry Louise Tyson

IPC: C07K16/24 ,  A61K39/395 ,  A61K9/00 ,  A61K39/00

CPC classification number: C07K16/244 ,  A61K9/0078 ,  A61K39/395 ,  A61K39/3955 ,  A61K2039/505 ,  A61K2039/544 ,  C07K2317/24 ,  C07K2317/33 ,  C07K2317/51 ,  C07K2317/515 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2317/94

Abstract: The invention relates to antibody molecules having specificity for antigenic determinants of human IL-13, therapeutic uses of the antibody molecules and methods for producing antibody molecules.

公开(公告)号：US09738710B2

公开(公告)日：2017-08-22

申请号：US14547291

申请日：2014-11-19

Applicant: UCB Biopharma SPRL

Inventor： Karen Margrete Miller ,  Marc Roger De Ryck ,  Christian Gilbert J. Wolff ,  Alastair David Griffiths Lawson ,  Helene Margaret Finney ,  Terence Seward Baker

IPC: A61K39/395 ,  C12P21/08 ,  C07K16/00 ,  C07K16/28 ,  A61K39/00 ,  C07K16/18

CPC classification number: C07K16/18 ,  C07K16/28 ,  C07K2317/34

Abstract: An anti-E1 ion channel antibody or binding fragment thereof, pharmaceutical compositions comprising said antibodies, use of the antibodies and compositions comprising the same, in treatment, for example in the treatment/modulation of pain and processes for generating and preparing said antibodies.

公开(公告)号：US20160289323A1

公开(公告)日：2016-10-06

申请号：US15180916

申请日：2016-06-13

Applicant: UCB BIOPHARMA SPRL

Inventor： Neil Gozzard ,  Alastair David Griffiths Lawson ,  Daniel John Lightwood ,  Roger Thomas Palframan ,  Bryan John Smith ,  Kerry Louise Tyson

IPC: C07K16/24 ,  A61K9/00 ,  A61K39/395

CPC classification number: C07K16/244 ,  A61K9/0078 ,  A61K39/395 ,  A61K39/3955 ,  A61K2039/505 ,  A61K2039/544 ,  C07K2317/24 ,  C07K2317/33 ,  C07K2317/51 ,  C07K2317/515 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2317/94

Abstract: The invention relates to antibody molecules having specificity for antigenic determinants of human IL-13, therapeutic uses of the antibody molecules and methods for producing said antibody molecules.

Abstract translation: 本发明涉及对人IL-13的抗原决定簇具有特异性的抗体分子，抗体分子的治疗用途以及产生所述抗体分子的方法。

公开(公告)号：US10233243B2

公开(公告)日：2019-03-19

申请号：US14400812

申请日：2013-05-13

Applicant: UCB Biopharma SPRL

Inventor： Helene Margaret Finney ,  Alastair David Griffiths Lawson ,  Stevan Graham Shaw ,  Bryan John Smith ,  Kerry Louise Tyson ,  Lara Kevorkian ,  Christoph Meier ,  Kaushik Sarkar ,  Paul Alan Atherfold

IPC: C07K16/00 ,  C12P21/08 ,  A61K39/395 ,  C07K16/28 ,  G01N33/50 ,  G01N33/564 ,  G01N33/68 ,  A61K47/60 ,  A61K47/64 ,  C07K1/00 ,  A61K39/00

Abstract: The disclosure relates to antibodies specific to FcRn, formulations comprising the same, use of each in therapy, processes for expressing and optionally formulating said antibody, DNA encoding the antibodies and hosts comprising said DNA.

公开(公告)号：US09266953B2

公开(公告)日：2016-02-23

申请号：US14585406

申请日：2014-12-30

Applicant: UCB BIOPHARMA SPRL

Inventor： Helene Margaret Finney ,  Terence Seward Baker ,  Alastair David Griffiths Lawson ,  Karen Margrete Miller ,  Marc Roger de Ryck ,  Christian Gilbert J. Wolff

IPC: A61K39/395 ,  C12P21/08 ,  C07K16/00 ,  C07K16/28 ,  A61K39/00

CPC classification number: C07K16/28 ,  A61K39/3955 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/34 ,  C07K2317/54 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/76

Abstract: A Nav1.7 binding entity that after binding functionally modifies the activity of the ion channel, in particular an anti-Nav1.7 antibody or binding fragment thereof, pharmaceutical compositions comprising said antibodies, use of the antibodies and compositions comprising the same, in treatment, for example in the treatment/modulation of pain and processes for generating and preparing said antibodies.

Abstract translation: 结合后的Nav1.7结合实体功能性地修饰离子通道的活性，特别是抗Nav1.7抗体或其结合片段，包含所述抗体的药物组合物，使用抗体及其组合物在治疗中 ，例如在疼痛的治疗/调节中以及产生和制备所述抗体的方法。

公开(公告)号：US20190248890A1

公开(公告)日：2019-08-15

申请号：US16271086

申请日：2019-02-08

Applicant: UCB Biopharma SPRL

Inventor： Helene Margaret Finney ,  Alastair David Griffiths Lawson ,  Stevan Graham Shaw ,  Bryan John Smith ,  Kerry Louise Tyson ,  Lara Kevorkian ,  Christoph Meier ,  Kaushik Sarkar ,  Paul Alan Atherfold

IPC: C07K16/28 ,  A61K39/395 ,  A61K47/64 ,  G01N33/50 ,  G01N33/564 ,  G01N33/68 ,  A61K47/60

CPC classification number: C07K16/283 ,  A61K39/3955 ,  A61K47/60 ,  A61K47/643 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/33 ,  C07K2317/55 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/92 ,  G01N33/5047 ,  G01N33/564 ,  G01N33/6854 ,  G01N33/6857 ,  G01N33/6893 ,  G01N2333/70535 ,  G01N2500/02 ,  G01N2500/10 ,  G01N2800/104 ,  G01N2800/24 ,  G01N2800/28

Abstract: The disclosure relates to antibodies specific to FcRn, formulations comprising the same, use of each in therapy, processes for expressing and optionally formulating said antibody, DNA encoding the antibodies and hosts comprising said DNA.

公开(公告)号：US20180346561A1

公开(公告)日：2018-12-06

申请号：US15974407

申请日：2018-05-08

Applicant: UCB BIOPHARMA SPRL

Inventor： Ralph Adams ,  Terence Seward Baker ,  Alastair David Griffiths Lawson

IPC: C07K16/24

CPC classification number: C07K16/244 ,  C07K2317/33 ,  C07K2317/92

Abstract: The invention relates to antibody molecules having specificity for antigenic determinants of both IL-17A and IL-17F, therapeutic uses of the antibody molecules and methods for producing said antibody molecules.

公开(公告)号：US20160222107A1

公开(公告)日：2016-08-04

申请号：US15014145

申请日：2016-02-03

Applicant: UCB Biopharma SPRL

Inventor： Helene Margaret Finney ,  Terence Seward Baker ,  Alastair David Griffiths Lawson ,  Karen Margrete Miller ,  Marc Roger de Ryck ,  Christian Gilbert J. Wolff

IPC: C07K16/28 ,  A61K39/395

CPC classification number: C07K16/28 ,  A61K39/3955 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/34 ,  C07K2317/54 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/76

Abstract: A Nav1.7 binding entity that after binding functionally modifies the activity of the ion channel, in particular an anti-Nav1.7 antibody or binding fragment thereof, pharmaceutical compositions comprising said antibodies, use of the antibodies and compositions comprising the same, in treatment, for example in the treatment/modulation of pain and processes for generating and preparing said antibodies.

Abstract translation: 结合后的Nav1.7结合实体功能性地修饰离子通道的活性，特别是抗Nav1.7抗体或其结合片段，包含所述抗体的药物组合物，使用抗体及其组合物在治疗中 ，例如在疼痛的治疗/调节中以及产生和制备所述抗体的方法。

公开(公告)号：US20150218271A1

公开(公告)日：2015-08-06

申请号：US14690892

申请日：2015-04-20

Applicant: UCB Biopharma SPRL

Inventor： Ralph Adams ,  Terence Seward Baker ,  Alastair David Griffiths Lawson

IPC: C07K16/24

CPC classification number: C07K16/244 ,  C07K2317/33 ,  C07K2317/92

Abstract: The invention relates to antibody molecules having specificity for antigenic determinants of both IL-17A and IL-17F, therapeutic uses of the antibody molecules and methods for producing said antibody molecules.

Abstract translation: 本发明涉及对IL-17A和IL-17F的抗原决定簇具有特异性的抗体分子，抗体分子的治疗用途和产生所述抗体分子的方法。